H.C. Wainwright analyst Edward White reiterated a Buy rating on Curis (CRIS – Research Report) yesterday and set a price target of $16.00.
Edward White has given his Buy rating due to a combination of factors related to Curis’s promising developments in their clinical trials. The company’s TakeAim Lymphoma study, which is now registrational, is evaluating emavusertib, a novel IRAK4 inhibitor, for treating acute myeloid leukemia and non-Hodgkin’s lymphoma. Significant progress has been made in the trial, particularly for patients with relapsed or refractory primary CNS lymphoma (pCNSL), where emavusertib has shown encouraging results in reducing tumor burden and achieving objective responses.
Curis’s strategy to pursue accelerated approval for emavusertib in pCNSL is supported by successful discussions with regulatory bodies like the FDA and EMA. The company is actively enrolling additional patients to strengthen their regulatory submission, with a focus on demonstrating a consistent overall response rate. Given the lack of approved therapies for r/r pCNSL, the potential for emavusertib to fill this gap, alongside projected sales growth, underpins Edward White’s optimistic outlook and Buy rating for Curis’s stock.
CRIS’s price has also changed dramatically for the past six months – from $5.390 to $2.100, which is a -61.04% drop .